Ann: Appendix 4C - March 2018 Quarterly Report, page-20

There is another near term catalyst which is highlighted in Bold below, twice....
PromarkerD, the world leading predictive diagnostic test for diabetic kidney disease, launched in Dominican Republic 
In clinical studies the PromarkerD test predicted 86% of previously disease-free patients who went on to develop chronic kidney disease within four years 
In March 2017, Frost & Sullivan identified PromarkerD as the world's leading test for diabetic kidney disease 
422 million people have diabetes and approximately one third are expected to develop diabetic kidney disease  PromarkerD has the potential to save healthcare systems around the world billions of dollars in costs associated with treating diabetic kidney disease 
The Company expects to be in a position to update the market on further licensing deals in the near future Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) announces the official product launch of its world leading predictive diagnostic test for diabetic kidney disease, “PromarkerD”.
The pioneering diagnostic test was launched overnight by Proteomics International’s partner Omics Global Solutions (Puerto Rico, USA) through its distributor in the Dominican Republic, Macrotech Farmacéutica, the exclusive provider of dialysis services in the country.
The successful launch represents the achievement of a key milestone in the stepped approach to commercialise the test in global markets using a range of technology platforms. Proteomics International is engaged with potential partners to bring PromarkerD to market in mainland USA, Mexico, Japan, Australia, China and Europe. Proteomics International's Managing Director, Dr Richard Lipscombe said, “The world is now recognising the growing burden of diabetes and the importance of kidney health. We see PromarkerD as transforming the diagnosis and treatment of diabetic kidney disease and saving healthcare systems many millions of dollars.”
The test is being provided using the published mass spectrometry technology platform, known as a Laboratory Developed Test (LDT), and the Company expects to conclude its next licensing deal for this version of PromarkerD with a certified laboratory within weeks.
Following uptake by specialised facilities, Proteomics International is focused on finalising the development of the in vitro diagnostic (IVD) immunoassay version of PromarkerD, that can be used in clinical laboratories around the world.
That will give the SP a push.... More Markets = More Money